Approximately 30% of patients with MDS progress to acute myeloid leukemia 1 .
Thus, it is important to identify risk factors for AML progression and for the mortality of these patients, to guide treatment decisions. The Hedgehog (Hh) pathway is an important mediator of early hematopoietic development 2 and, for the last two decades, a number of studies have linked an abnormal Hh signaling to distinct human malignancies 3 . Previous evidence has suggested that Hh signaling plays a role in hematopoietic malignancies 4 Recently, experimental data have shown that SMO was significantly increased in a mouse model for familial adenomatous polyposis. The authors also mentioned that SMO expression was increased in 9 out of 20 cancer samples compared with the normal epithelium of the same patients. Unexpectedly, in that study, reduced expression of SMO did not suppress GLI-dependent Hh signaling in intestinal tumor cells, suggesting that SMO could contribute to the proliferation of those cells by a mechanism independent of GLI-mediated transcription 12 .
In our study, Kaplan-Meier analysis indicated a 5-year EFS of 31 versus 53% for patients with higher SMO expression (above median) versus lower SMO expression, respectively (P= 0.04; Figure 1F ). The same was observed for 5-year AML evolution (49%>1.74 SMO versus 91% <1.74 SMO; P= 0.002, Figure 1G ). Univariate analysis showed that WHO diagnosis of RAEB-1 and 
